Marriott Harrison advises on AIM IPO of SalvaRx Group PLC

Friday 1 April 2016

Corporate partner Simon Charles and corporate associate David Bettis advised Northland Capital Partners Limited in its capacity as nominated adviser and broker to SalvarRx Group PLC, a drug discovery and development company which focuses on immuno oncology and which invests in novel cancer immuno-therapies, on its admission to AIM and related equity issue.

MH Corporate